141 related articles for article (PubMed ID: 10666513)
1. LY354740 affects startle responding but not sensorimotor gating or discriminative effects of phencyclidine.
Schreiber R; Lowe D; Voerste A; De Vry J
Eur J Pharmacol; 2000 Jan; 388(2):R3-4. PubMed ID: 10666513
[TBL] [Abstract][Full Text] [Related]
2. Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of positive schizophrenia symptoms and cognition.
Schlumberger C; Schäfer D; Barberi C; Morè L; Nagel J; Pietraszek M; Schmidt WJ; Danysz W
Behav Pharmacol; 2009 Feb; 20(1):56-66. PubMed ID: 19179851
[TBL] [Abstract][Full Text] [Related]
3. The anxiolytic action of mGlu2/3 receptor agonist, LY354740, in the fear-potentiated startle model in rats is mechanistically distinct from diazepam.
Tizzano JP; Griffey KI; Schoepp DD
Pharmacol Biochem Behav; 2002 Sep; 73(2):367-74. PubMed ID: 12117591
[TBL] [Abstract][Full Text] [Related]
4. The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats.
Cartmell J; Monn JA; Schoepp DD
J Pharmacol Exp Ther; 1999 Oct; 291(1):161-70. PubMed ID: 10490900
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the mGlu(5) receptor positive allosteric modulator ADX47273 and the mGlu(2/3) receptor agonist LY354740 in tests for antipsychotic-like activity.
Schlumberger C; Pietraszek M; Gravius A; Klein KU; Greco S; Morè L; Danysz W
Eur J Pharmacol; 2009 Nov; 623(1-3):73-83. PubMed ID: 19765575
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo evidence for a lack of interaction with dopamine D2 receptors by the metabotropic glutamate 2/3 receptor agonists 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-bicaroxylate monohydrate (LY354740) and (-)-2-oxa-4-aminobicyclo[3.1.0] Hexane-4,6-dicarboxylic acid (LY379268).
Fell MJ; Perry KW; Falcone JF; Johnson BG; Barth VN; Rash KS; Lucaites VL; Threlkeld PG; Monn JA; McKinzie DL; Marek GJ; Svensson KA; Nelson DL
J Pharmacol Exp Ther; 2009 Dec; 331(3):1126-36. PubMed ID: 19755662
[TBL] [Abstract][Full Text] [Related]
7. Improved bioavailability of the mGlu2/3 receptor agonist LY354740 using a prodrug strategy: in vivo pharmacology of LY544344.
Rorick-Kehn LM; Perkins EJ; Knitowski KM; Hart JC; Johnson BG; Schoepp DD; McKinzie DL
J Pharmacol Exp Ther; 2006 Feb; 316(2):905-13. PubMed ID: 16223873
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039).
Rorick-Kehn LM; Johnson BG; Burkey JL; Wright RA; Calligaro DO; Marek GJ; Nisenbaum ES; Catlow JT; Kingston AE; Giera DD; Herin MF; Monn JA; McKinzie DL; Schoepp DD
J Pharmacol Exp Ther; 2007 Apr; 321(1):308-17. PubMed ID: 17204749
[TBL] [Abstract][Full Text] [Related]
9. Group II mGluR agonist LY354740 and NAAG peptidase inhibitor effects on prepulse inhibition in PCP and D-amphetamine models of schizophrenia.
Profaci CP; Krolikowski KA; Olszewski RT; Neale JH
Psychopharmacology (Berl); 2011 Jul; 216(2):235-43. PubMed ID: 21327758
[TBL] [Abstract][Full Text] [Related]
10. Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex.
Marek GJ; Wright RA; Schoepp DD; Monn JA; Aghajanian GK
J Pharmacol Exp Ther; 2000 Jan; 292(1):76-87. PubMed ID: 10604933
[TBL] [Abstract][Full Text] [Related]
11. The mGluR5 antagonist MPEP, but not the mGluR2/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity.
Henry SA; Lehmann-Masten V; Gasparini F; Geyer MA; Markou A
Neuropharmacology; 2002 Dec; 43(8):1199-209. PubMed ID: 12527469
[TBL] [Abstract][Full Text] [Related]
12. A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity.
Galici R; Echemendia NG; Rodriguez AL; Conn PJ
J Pharmacol Exp Ther; 2005 Dec; 315(3):1181-7. PubMed ID: 16123306
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, SARs, and pharmacological characterization of 2-amino-3 or 6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent, selective, and orally active group II metabotropic glutamate receptor agonists.
Nakazato A; Kumagai T; Sakagami K; Yoshikawa R; Suzuki Y; Chaki S; Ito H; Taguchi T; Nakanishi S; Okuyama S
J Med Chem; 2000 Dec; 43(25):4893-909. PubMed ID: 11123999
[TBL] [Abstract][Full Text] [Related]
14. Anxiolytic-like activity of the mGLU2/3 receptor agonist LY354740 in the elevated plus maze test is disrupted in metabotropic glutamate receptor 2 and 3 knock-out mice.
Linden AM; Shannon H; Baez M; Yu JL; Koester A; Schoepp DD
Psychopharmacology (Berl); 2005 Apr; 179(1):284-91. PubMed ID: 15619115
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors.
Monn JA; Valli MJ; Massey SM; Hansen MM; Kress TJ; Wepsiec JP; Harkness AR; Grutsch JL; Wright RA; Johnson BG; Andis SL; Kingston A; Tomlinson R; Lewis R; Griffey KR; Tizzano JP; Schoepp DD
J Med Chem; 1999 Mar; 42(6):1027-40. PubMed ID: 10090786
[TBL] [Abstract][Full Text] [Related]
16. Effects of the group II metabotropic glutamate receptor agonist, LY354740 on schedule-controlled behaviour in rats.
Moore NA; Rees G; Monn JA
Behav Pharmacol; 1999 May; 10(3):319-25. PubMed ID: 10780246
[TBL] [Abstract][Full Text] [Related]
17. Lack of effect of LY314582 (a group 2 metabotropic glutamate receptor agonist) on phencyclidine-induced locomotor activity in metabotropic glutamate receptor 2 knockout mice.
Spooren WP; Gasparini F; van der Putten H; Koller M; Nakanishi S; Kuhn R
Eur J Pharmacol; 2000 May; 397(1):R1-2. PubMed ID: 10844118
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotective and behavioral effects of the selective metabotropic glutamate mGlu(1) receptor antagonist BAY 36-7620.
De Vry J; Horváth E; Schreiber R
Eur J Pharmacol; 2001 Oct; 428(2):203-14. PubMed ID: 11675037
[TBL] [Abstract][Full Text] [Related]
19. Transepithelial transport of the group II metabotropic glutamate 2/3 receptor agonist (1S,2S,5R,6S)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate (LY354740) and its prodrug (1S,2S,5R,6S)-2-[(2'S)-(2'-amino)propionyl]aminobicyclo[3.1.0]hexane-2,6-dicarboxylate (LY544344).
Varma MV; Eriksson AH; Sawada G; Pak YA; Perkins EJ; Zimmerman CL
Drug Metab Dispos; 2009 Jan; 37(1):211-20. PubMed ID: 18838508
[TBL] [Abstract][Full Text] [Related]
20. Potent, stereoselective, and brain region selective modulation of second messengers in the rat brain by (+)LY354740, a novel group II metabotropic glutamate receptor agonist.
Schoepp DD; Johnson BG; Wright RA; Salhoff CR; Monn JA
Naunyn Schmiedebergs Arch Pharmacol; 1998 Aug; 358(2):175-80. PubMed ID: 9750002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
